Benzinga | Nov 23, 2020 08:10AM EST

Halozyme Raises FY20 GAAP EPS Guidance From $0.80-$0.85 To $0.90-$0.95 vs $0.86 Est., Raises Sales Guidance From $250M-$260M To $265M-$275M vs $255.12M

SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and license agreement with Horizon Therapeutics plc.

The Company is raising full year 2020 revenue guidance to $265 million to $275 million to reflect incremental anticipated revenues as Halozyme and its partners continue to execute on a number of fourth quarter revenue-related activities.

The Company now expects:

* Revenues of $265 million to $275 million, increased from prior guidance of $250 million to $260 million, representing growth of 35% to 40% over prior year revenues;

* Earnings per share on a GAAP basis of $0.90 to $0.95, increased from prior guidance of $0.80 to $0.85.